Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Sperling AS, et al. Among authors: kennedy ja. Blood. 2022 Oct 20;140(16):1753-1763. doi: 10.1182/blood.2021014956. Blood. 2022. PMID: 35512188 Free PMC article.
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, Sukhai M, Thomas M, Bartoszko J, Ho J, Siddiq N, Maze D, Schimmer A, Schuh A, Sibai H, Yee K, Claudio J, Devlin R, Minden MD, Kamel-Reid S, Gupta V. Spiegel JY, et al. Among authors: kennedy ja. Blood Adv. 2017 Sep 8;1(20):1729-1738. doi: 10.1182/bloodadvances.2017009530. eCollection 2017 Sep 12. Blood Adv. 2017. PMID: 29296819 Free PMC article.
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V. McNamara CJ, et al. Among authors: kennedy ja. Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469. Blood Adv. 2018. PMID: 30327374 Free PMC article.
Modeling and targeting of erythroleukemia by hematopoietic genome editing.
Iacobucci I, Qu C, Varotto E, Janke LJ, Yang X, Seth A, Shelat A, Friske JD, Fukano R, Yu J, Freeman BB, Kennedy JA, Sperling AS, Zheng R, Wang Y, Jogiraju H, Dickerson KM, Payne-Turner D, Morris SM, Hollis ES, Ghosn N, Haggard GE, Lindsley RC, Ebert BL, Mullighan CG. Iacobucci I, et al. Among authors: kennedy ja. Blood. 2021 Mar 25;137(12):1628-1640. doi: 10.1182/blood.2020009103. Blood. 2021. PMID: 33512458 Free PMC article.
304 results